(Q47753506)

5 February 2018

title

Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM. (English)

1 reference

5 February 2018

author name string

A H E Herbers

1 reference

5 February 2018

W J F M van der Velden

1 reference

5 February 2018

A F J de Haan

1 reference

5 February 2018

J P Donnelly

1 reference

5 February 2018

N M A Blijlevens

1 reference

5 February 2018

language of work or name

English

0 references

publication date

19 August 2013

1 reference

5 February 2018

Bone Marrow Transplantation

published in

1 reference

5 February 2018

volume

1 reference

5 February 2018

issue

1 reference

5 February 2018

page(s)

8-10

1 reference

5 February 2018

Palifermin for oral mucositis after intensive therapy for hematologic cancers

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.118

In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.118

Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.118

Gut protection by palifermin during autologous haematopoietic SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.118

Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.118

Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.118

Colonization and molecular epidemiology of coagulase-negative Staphylococcal bacteremia in cancer patients: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.118

Bacteraemia coincides with low citrulline concentrations after high-dose melphalan in autologous HSCT recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.118

Febrile mucositis in haematopoietic SCT recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.118

Palifermin mediates immunoregulatory effects in addition to its cytoprotective effects in mice with acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.118

Keratinocyte growth factor protects alveolar epithelium and endothelium from oxygen-induced injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.118

Palifermin induces alveolar maintenance programs in emphysematous mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.118

The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies

21 January 2018

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury

1 reference

PubMed

12 December 2020

Origins of Staphylococcus epidermidis and Streptococcus oralis causing bacteraemia in a bone marrow transplant patient

1 reference

PubMed

12 December 2020

Identifiers

DOI

10.1038/BMT.2013.118

1 reference

5 February 2018

1 reference

5 February 2018